- The shares of Taysha Gene Therapies (TSHA) recently received a $19 price target. These are the details.
The shares of Taysha Gene Therapies (TSHA) recently received a $19 price target.
Price target: Reduced from $22 to $19
Rating: Buy
Analyst firm: Guggenheim
Guggenheim analysts adjusted the rating while noting that the one-two punch of business development and an opportunistic capital markets transaction increased the cash runway into the first quarter of 2024. And the analysts pointed out that the January 2023 FDA feedback on GAN will be key to sentiment.
